Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide (Q39905603)

15 September 2017

Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide (English)

1 reference

15 September 2017

0 references

1 reference

5

Keith T Flaherty

1 reference

15 September 2017

6

Dagmar Kulms

1 reference

15 September 2017

10

Claus Garbe

1 reference

15 September 2017

3

Heike Niessner

1 reference

15 September 2017

9

Jeannette Gogel

1 reference

15 September 2017

1

Tobias Sinnberg

1 reference

15 September 2017

7

Evelyn Maczey

1 reference

15 September 2017

11

Friedegund Meier

1 reference

15 September 2017

Konstantinos Lasithiotakis

series ordinal

2

1 reference

15 September 2017

Birgit Schittek

series ordinal

4

1 reference

15 September 2017

Minia Campos

series ordinal

8

1 reference

15 September 2017

language of work or name

English

0 references

publication date

11 December 2008

1 reference

Journal of Investigative Dermatology

15 September 2017

1 reference

15 September 2017

129

1 reference

15 September 2017

6

1 reference

15 September 2017

1500-1515

1 reference

https://scigraph.springernature.com/pub.10.1038/jid.2008.379

15 September 2017

0 references

cites work

Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Apoptosis regulators and responses in human melanocytic and keratinocytic cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

The role of Bcl-2 family members in the progression of cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Chemotherapy and targeted therapy combinations in advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Exploring the specificity of the PI3K family inhibitor LY294002.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Chemotherapy for metastatic melanoma: time for a change?

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

B-RAF is a therapeutic target in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

LY294002 inhibits LPS-induced NO production through a inhibition of NF-kappaB activation: independent mechanism of phosphatidylinositol 3-kinase

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Ras/Raf signalling and emerging pharmacotherapeutic targets

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Human melanoma progression in skin reconstructs : biological significance of bFGF.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

New techniques for the in vitro culture of human skin keratinocytes and perspectives on their use for grafting of patients with extensive burns

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

PED mediates AKT-dependent chemoresistance in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

LY-294002 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] affects calcium signaling in airway smooth muscle cells independently of phosphoinositide 3-kinase inhibition

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

V599EB-RAF is an oncogene in melanocytes

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

A fluorometric rapid microassay to identify anti-proliferative compounds for human melanoma cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.379

7 January 2021

Identifiers

DOI

10.1038/JID.2008.379

1 reference

15 September 2017

1 reference